Your Health, We Care
Release date: 2026-05-09 15:41:32 Recommended: 9
In addition to common gastrointestinal reactions, semaglutide tablets may cause some serious side effects requiring emergency medical attention: including pancreatitis (manifested as persistent severe abdominal pain that may radiate to the back), vision changes, severe allergic reactions (swelling of the face or throat, difficulty breathing or swallowing, severe rash or itching, very fast heartbeat), gallbladder problems (upper abdominal pain, yellowing of the skin or eyes, fever, clay-colored stools), and kidney injury due to dehydration. Additionally, because this medication slows gastric emptying, it may increase the risk of food or liquid entering the lungs during surgery or when using anesthesia or deep sedation. Therefore, you must inform all medical personnel that you are taking semaglutide tablets before surgery. A practical tip to help establish the routine of taking the tablet on an empty stomach every morning: place the semaglutide tablet bottle and a small cup of plain water on your bedside table. After waking up in the morning, the first thing you do is take the tablet with no more than 4 ounces of water, then proceed with daily activities such as brushing your teeth and getting dressed, and wait 30 minutes before eating breakfast or taking other medications. If you miss a dose, skip the missed dose and take the next dose as usual the following day. Do not double the dose.
In addition to lowering blood sugar and reducing weight, semaglutide tablets have been specifically validated for cardiovascular safety. A cardiovascular outcomes study enrolled 3,183 adults with type 2 diabetes who were at high risk of cardiovascular events. These participants, while receiving conventional glucose-lowering and cardiovascular drug therapy, were randomly assigned to receive either 14 mg of semaglutide tablets or placebo once daily. The study results showed that semaglutide tablets did not increase the risk of major cardiovascular events such as heart attack, stroke, or death. In other words, for patients with type 2 diabetes who already have high cardiovascular risk factors, using semaglutide tablets does not pose additional cardiovascular safety concerns. This conclusion is particularly important for patients who need to manage both blood sugar and cardiovascular risk, allowing physicians and patients to choose this medication as part of the treatment plan with greater confidence.
Semaglutide tablets are a GLP-1 (glucagon-like peptide-1) medication whose mechanism of action differs from any other oral glucose-lowering drug. It mimics the body's own GLP-1 hormone and works through three pathways to lower blood glucose synergistically. First: when blood sugar levels rise, it stimulates the pancreas to release more insulin, directly helping glucose enter cells to be used. Second: it inhibits the liver from producing and releasing excess sugar, preventing the liver from becoming an "additional source" of blood glucose. Third: it slows down the emptying of food from the stomach into the intestines after meals, thereby allowing glucose to be absorbed slowly and preventing sharp spikes in postprandial blood sugar. These three mechanisms complement each other, making the glucose-lowering effect more stable and sustained. Semaglutide tablets are the first and only GLP-1 medication available in tablet form; previously, such medications could only be administered by injection, so the tablet form greatly facilitates long-term patient adherence.
